PEDIATRICS Vol. 91 No. 3 March 1993, pp. 537-539
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kappas, A.
Right arrow Articles by Galbraith, R. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kappas, A.
Right arrow Articles by Galbraith, R. A.

Prolonged Clinical Use of a Heme Oxygenase Inhibitor: Hematological Evidence for an Inducible but Reversible Iron-Deficiency State

Attallah Kappas MD1, George S. Drummond PhD1, and Richard A. Galbraith FRCP1

1 From The Rockefeller University Hospital, New York, NY.

The heme oxygenase inhibitor tin (Sn4+)-mesoporphyrin, administered to two 17-year-old Crigler-Najjar type I patients during a 400-day study to lower plasma bilirubin levels, also produced changes, beginning ~50 days after initiation of treatment, in hematological and iron metabolism indices consistent with the development of iron deficiency anemia. These indices were responsive to iron supplementation and re verted to normal after termination of inhibitor treatment. Tin-mesoporphyrin enhances biliary heme excretion and inhibits intestinal heme oxygenase when administered orally or parenterally; the changes in blood indices could thus reflect, in part, blockade of heme catabolism and therefore of uptake of heme-derived iron, by intestinal epithelium. This action of the inhibitor suggests that such agents may facilitate studies involving aberrant metabolism of heme-derived iron in humans and that they merit further investigation with respect to their potential value in enhancing iron disposal in certain disorders such as those related, for example, to transfusion-induced iron overload states.

Key Words: tin-mesoporphyrin • heme oxygenase inhibitors • iron deficiency

Submitted on July 8, 1992
Accepted on September 15, 1992




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
L. Wu and R. Wang
Carbon Monoxide: Endogenous Production, Physiological Functions, and Pharmacological Applications
Pharmacol. Rev., December 1, 2005; 57(4): 585 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
F. A. D. T. G. Wagener, H.-D. Volk, D. Willis, N. G. Abraham, M. P. Soares, G. J. Adema, and C. G. Figdor
Different Faces of the Heme-Heme Oxygenase System in Inflammation
Pharmacol. Rev., September 1, 2003; 55(3): 551 - 571.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. D. Lutton, N. G. Abraham, G. S. Drummond, R. D. Levere, and A. Kappas
Zinc porphyrins: Potent inhibitors of hematopoieses in animal and human bone marrow
PNAS, February 18, 1997; 94(4): 1432 - 1436.
[Abstract] [Full Text] [PDF]